Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05060003
Recruitment Status : Not yet recruiting
First Posted : September 28, 2021
Last Update Posted : September 28, 2021
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
This study's hypothesis is that patients with stage II melanoma who test positive for circulating tumor DNA are at a higher risk for recurrence and therefore adjuvant treatment is justified. In this study, the blood of consenting and eligible patients will be tested for ctDNA and those patients who test positive will be randomized on a 1:1 basis to either treatment with atezolizumab and tiragolumab or atezolizumab alone during Stage 1 of the study. If at least 3 patients in the atezolizumab + tiragolumab arm are shown to be ctDNA negative at C3D1, stage 2 of the study will begin enrollment. Stage 2 consists of 25 patients all enrolled to the atezolizumab + tiragolumab arm (no randomization and no atezolizumab monotherapy arm).Patients who test negative for ctDNA will be observed off protocol.

Condition or disease Intervention/treatment Phase
Stage II Melanoma Drug: Atezolizumab Drug: Tiragolumab Procedure: ctDNA Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 244 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Estimated Study Start Date : December 31, 2021
Estimated Primary Completion Date : February 28, 2024
Estimated Study Completion Date : December 31, 2027

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Arm 1: Atezolizumab + Tiragolumab
  • Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).
  • Tiragolumab is given as an IV infusion every 4 weeks at a dose of 840 mg over 60 minutes (+/- 15 minutes).
  • Treatment can continue for up to 13 cycles.
Drug: Atezolizumab
Atezolizumab is provided by Genentech.
Other Name: Tecentriq

Drug: Tiragolumab
Tiragolumab is provided by Genentech.

Procedure: ctDNA
Pre-screening/baseline (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)

Active Comparator: Arm 2: Atezolizumab
  • Atezolizumab is given as an IV infusion every 4 weeks at a dose of 1680 mg over 60 minutes (+/- 15 minutes).
  • Treatment can continue for up to 13 cycles.
Drug: Atezolizumab
Atezolizumab is provided by Genentech.
Other Name: Tecentriq

Procedure: ctDNA
Pre-screening/baseline (4-12 weeks after date of surgery), cycle 3 day 1, cycle 6 day 1, cycle 9 day 1, cycle 12 day 1, and end of treatment (optional)




Primary Outcome Measures :
  1. ctDNA clearance rate [ Time Frame: Cycle 3 Day 1 (estimated to be 8 weeks) ]
    -Defined as the proportion of ctDNA-positive participants having a ctDNA-negative test at Cycle 3 Day 1


Secondary Outcome Measures :
  1. Proportion of ctDNA-positive participants having a ctDNA-negative test at two consecutive measures [ Time Frame: From baseline to end of treatment (estimated to be 12 months) ]
  2. Relapse-free survival (RFS) [ Time Frame: Through completion of follow-up (estimated to be 48 months) ]
    -Defined as the duration of time from the date of randomization to the date of earliest disease relapse or death, whichever occurs first.

  3. Distant metastasis-free survival (DMFS) [ Time Frame: Through completion of follow-up (estimated to be 48 months) ]
    -Defined as as the duration of time from the date of positive ctDNA being confirmed to the date of appearance of a distant metastasis or death, whichever occurs first.

  4. Overall survival (OS) [ Time Frame: Through completion of follow-up (estimated to be 48 months) ]
    -Defined as the duration of time from the date of positive ctDNA being confirmed to death from any cause.

  5. Number of treatment-related grade 3 or greater adverse events [ Time Frame: From baseline through 90 days after end of treatment (estimated to be 15 months) ]
  6. Number of treatment discontinuations due to treatment-related adverse events [ Time Frame: From start of treatment through completion of treatment (estimated to be 12 months) ]
  7. Assess the impact of ctDNA kinetics on relapse-free survival [ Time Frame: Through completion of follow-up (estimated to be 48 months) ]
  8. Assess the impact of ctDNA kinetics on distant metastasis-free survival [ Time Frame: Through completion of follow-up (estimated to be 48 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Surgically resected and histologically/pathologically confirmed stage II cutaneous melanoma. No more than 16 weeks may elapse between final surgical resection and randomization. Treatment should start only after complete wound healing from the surgery.
  • Participants must not have been previously treated for melanoma beyond complete surgical resection.
  • Positive ctDNA test
  • At least 18 years of age.
  • ECOG performance status ≤ 1
  • Normal bone marrow and organ function as defined below:

    • Absolute neutrophil count ≥ 1,500/mcL
    • Lymphocyte count ≥ 500/mcL
    • Platelets ≥ 100,000/mcL
    • Hemoglobin ≥ 9.0 g/dL (patients may be transfused to meet this criterion)
    • Total bilirubin ≤ 1.5 x IULN or direct bilirubin ≤ IULN for participants with total bilirubin levels > 1.6 x IULN; patients with known Gilbert disease must have total bilirubin ≤ 3 x IULN
    • AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN
    • Alkaline phosphatase ≤ 2.5 x IULN
    • Creatinine clearance ≥ 45 mL/min by Cockcroft-Gault
    • Serum albumin ≥ 2.5 g/dL
    • INR or PT ≤ 1.5 x IULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
    • aPTT ≤ 1.5 x IULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
  • The effects of atezolizumab and tiragolumab on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation, for 90 days after the final dose of tiragolumab, and for 5 months after the final dose of atezolizumab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 90 days after completion of the study
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

  • A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease or malignancies in situ (such as DCIS), basal cell carcinoma, or localized cutaneous squamous cell carcinomas.
  • Prior systemic therapy for melanoma.
  • Currently receiving any other investigational agents.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab and tiragolumab or other agents used in the study.
  • Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
  • Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the exceptions listed below:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
    • Rash must cover < 10% of body surface area

      • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
      • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months
  • Active tuberculosis.
  • Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study.
  • Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
  • Prior allogeneic stem cell or solid organ transplantation
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
  • Positive hepatitis B surface antigen (HBsAb) at screening.
  • Positive hepatitis C virus (HCV) antibody test at screening (unless followed by a negative HCV RNA test).
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment, within 90 days after the final dose of tiragolumab, or within 5 months after the final dose of atezolizumab
  • Current treatment with anti-viral therapy for HBV
  • Positive Epstein-Barr virus (EBV) viral capsid antigen immunoglobulin M (IgM) test at screening. An EBV PCR test should be performed as clinically indicated to screen for acute infection or suspected chronic active infection. Patients with a positive EBV PCR test are excluded.
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies.
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment.
  • Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor-α [TNF-α] agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

    • Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study
    • Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05060003


Contacts
Layout table for location contacts
Contact: George Ansstas, M.D. 314-362-5677 gansstas@wustl.edu

Locations
Layout table for location information
United States, California
City of Hope
Duarte, California, United States, 91010
Contact: Yan Xing, M.D., Ph.D.    626-256-4673      
Principal Investigator: Yan Xing, M.D., Ph.D.         
University of California - San Francisco
San Francisco, California, United States, 94143
Contact: Adil Daud, M.D.    415-353-9900      
Principal Investigator: Adil Daud, M.D.         
United States, Connecticut
Yale School of Medicine
New Haven, Connecticut, United States, 06510
Contact: Mario Sznol, M.D.    203-200-6622    mario.sznol@yale.edu   
Principal Investigator: Mario Sznol, M.D.         
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Contact: George Ansstas, M.D.    314-362-5677    gansstas@wustl.edu   
Principal Investigator: George Ansstas, M.D.         
Sub-Investigator: David Chen, M.D.         
Sub-Investigator: Ningying Wu, Ph.D.         
United States, New York
Memorial Sloan Kettering
New York, New York, United States, 10065
Contact: Margaret Callahan, M.D., Ph.D.    646-888-5108    callaham@mskcc.org   
Principal Investigator: Margaret Callahan, M.D., Ph.D.         
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Contact: Meredith McKean, M.D., MPH    615-329-7274      
Principal Investigator: Meredith McKean, M.D., MPH         
Sponsors and Collaborators
Washington University School of Medicine
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: George Ansstas, M.D. Washington University School of Medicine
Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT05060003    
Other Study ID Numbers: 21-x233
First Posted: September 28, 2021    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Atezolizumab
Antineoplastic Agents